Active Startup: Kanyr Pharma

Published: 10 October 2019

Business Snapshot
Kanyr has proprietary data on their mechanism of action and a proprietary small molecule lead compound inhibitor allowing for the targeting of phosphatases of regenerating liver (PRLs) through a newly identified co-oncogenic partner.

Target Markets
Immunotherapy (cancer).

Intellectual Property
In prosecution in Canada, US, Europe, Japan, China.

Michel Tremblay

Back to top